Message From the Chief
Introducing the Barbara T. Murphy Division of Nephrology
The newly renamed Barbara T. Murphy Division of Nephrology moved forward on a broad variety of fronts in 2021.
Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai, including our Division of Nephrology, have long placed a special emphasis on translational research—moving discoveries from bench to bedside to make a real difference in our patients’ lives.
In 2021, as described in this report, we marked a major milestone in this area when Renalytix, a company co-founded by several Icahn Mount Sinai faculty members, brought its first product into clinical use: KidneyIntelX, which uses a proprietary algorithm and a variety of data inputs to assess disease progression risk among early-stage CKD patients with type 2 diabetes. The inputs include clinical data from patients’ electronic health records and three blood-based biomarkers.